Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. - Wikidata - awgldk - TriplyDB

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.

http://www.wikidata.org/entity/Q37999699

about

Management of bleeding and coagulopathy following major trauma: an updated European guideline.Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence Reversal of oral anticoagulation Anticoagulation drug therapy: a review Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism The Reversal of Direct Oral Anticoagulants in Animal Models.Direct anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patients.Diagnosis and Management of Acute Intracerebral Hemorrhage.Trends in the development of oral anticoagulants.Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices.Translational insights into traumatic brain injury occurring during dabigatran or warfarin anticoagulation.Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants.New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplasty Edoxaban: an update on the new oral direct factor Xa inhibitor.Anticoagulation in Patients Aged ≥75 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants.Management of acute stroke in patients taking novel oral anticoagulants.Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants.Treatment options for venous thromboembolism: lessons learnt from clinical trials.Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012 Emergency reversal of dabigatran for emergency surgery.Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults.Positive outcome after intentional overdose of dabigatran.Coagulation assessment with the new generation of oral anticoagulants.Intracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studies The perioperative management of treatment with anticoagulants and platelet aggregation inhibitors.Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association.Perioperative management of coagulation in nontraumatic intracerebral hemorrhage Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood A new era of stroke prevention in atrial fibrillation: comparing a new generation of oral anticoagulants with warfarin Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay.Rivaroxaban and hemostasis in emergency care.Current state of anticoagulants to treat deep venous thrombosis.The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor.Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation.Targeted Thromboelastographic (TEG) Blood Component and Pharmacologic Hemostatic Therapy in Traumatic and Acquired Coagulopathy.Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.Anticoagulants in atrial fibrillation patients with chronic kidney disease.Management of bleeding in patients receiving conventional or new anticoagulants: a practical and case-based approach.

P2860

Q21092902-B63A4DFE-CD15-4009-A080-893B98CAE336 Q26782483-BA437270-1E0F-43DD-9B04-D49DC041851F Q26827835-4B4C411C-D268-4714-A7FB-1E88710BE064 Q27021871-E35A6D52-DCDD-4810-927D-62C0B2FA5C39 Q28066262-FF8D2CDD-0CDE-43EF-A395-B1BDA1DE98E7 Q28076077-5368FF68-7AA0-4968-8890-61B0469EDEAF Q28087447-FC08D891-0633-47A4-88F3-051E0737F4B3 Q30491580-121D9CFE-4465-4F33-B0B3-F3A7E7ADC4FC Q30595943-48A5E8BA-ACE9-4423-A7ED-032FA328A674 Q31136660-6FB5C7E8-BB2A-4E09-B5B6-56515DE78E9E Q33424198-EA626C6F-23D4-4549-9B9E-C49E7798EDD4 Q33556350-DF9CC4FE-351D-4436-B207-615915E0BB84 Q33581189-3582DFB0-C132-419A-9292-D5CFCC17079D Q33854667-13BE8D2B-52C7-4087-BC50-F1EE36E97787 Q33891915-482165F2-A4D8-48E1-9761-A7A7AC8E78FF Q33935409-1DF7FDAA-C755-41AC-9518-EDB90465743A Q33936087-A7EBECE0-69ED-4C19-836C-68C934ED6A04 Q34111320-DA9255D6-2A9D-40E5-9EE4-6A56BF78DBC8 Q34497406-A096FAE9-B247-4429-B30F-04EC94240C8F Q34694544-546A96A2-FAD8-45C1-86DF-08D79195A9D3 Q34725585-473C6FF4-B2CC-44FB-B286-06CB712EE0B7 Q35578443-BAAFCE13-6EA8-4535-9F45-DE40A255AAFD Q36515685-0531CB53-09E7-4E1F-8B6C-C1EF68BBBFFF Q36852294-AA20A3F7-7876-4FAD-9E33-CF89F1082DF5 Q36968781-CE094AF5-5C89-4D27-93C6-EA7E048DB145 Q36984232-66C1B54D-47C3-4E88-A500-68BB125382D1 Q37194881-1E9A2E27-0539-4352-AE47-FC60390527FB Q37251490-B6554859-0011-4E06-ADC7-5AA7966A289D Q37274433-6A88537D-7A4D-4A2F-B12E-E4AC3DC6379F Q37297475-BB156DD6-0EF3-4AAE-8732-B7BA16E4867F Q37312021-BCFF7D24-0B69-40E0-8BF6-DBB2E4D72C10 Q37388007-70FC0E5A-AAA5-4F0C-9E9E-A6616900E5BA Q37631564-11555FF5-45EA-4DBC-97C6-F5F88704AEA3 Q37638073-6DAE4CAB-6A45-40EB-87C0-0042C72E197C Q37655400-C5773896-42A8-483D-A148-1F020E223040 Q37669387-817334DE-A027-40FC-864B-55E7D5020BC8 Q37731832-B3E3D30D-ECCD-499F-A0E1-7EB2C8125D4B Q38017613-8812E7CB-9F38-4F54-B947-E51892CE8954 Q38028855-70110BAA-380B-471E-99CC-34ECECE2AD8C Q38049617-8D406ACA-0BAA-4B98-A7B9-800876B5ABD6

P2860

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.

http://www.wikidata.org/entity/Q37999699

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.

@en

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.

@nl

type

label

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.

@en

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.

@nl

prefLabel

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.

@en

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.

@nl

P1433

Q37999699-A93A769A-67DF-4E76-A751-94B5F0AAD950

P1476

Q37999699-BE7B5692-CE4C-4CB8-A85E-00B710334F18

P2093

Q37999699-2C8F65EC-10E8-412A-B829-35F830E897F4

Q37999699-2CA9CE4B-3A99-4822-8AB3-ACD9FB511DBA

Q37999699-32D13AF5-4E79-41D1-A8B0-8010033CE425

Q37999699-882314B2-B6AD-45B7-8615-1557A53D508C

Q37999699-8DD89492-2448-4E91-889B-C89BC12A6438

Q37999699-984D9D4F-A42C-4629-8A36-F9EEF454A528

Q37999699-BE292B48-0FFA-48F2-8776-3DC29E3B3D0C

Q37999699-C4007A52-61C7-4C15-8715-0BC921568244

Q37999699-DFF227B7-F2A3-4DCE-9696-3AB4ED0CCD83

Q37999699-EA1BCC5A-A991-4B1D-A109-37D1D17042E4

P2860

Q37999699-120D9BB0-FD68-4F0E-A96E-9F09936EBA91

Q37999699-1E06BA71-29D0-47C6-8C2D-5FEAD4920944

Q37999699-303363B4-30AC-4646-B66D-276388AB73D8

Q37999699-37BDD61C-C3EF-49A6-86E0-C17806F32552

Q37999699-54D26EC5-B028-4DC4-8C5F-0C2970673370

Q37999699-827CDD00-8003-47F8-AD2B-F5FDBBAAEBDF

Q37999699-8F3EBD35-63EB-4839-A031-4A1F083C157C

Q37999699-9F9F77B1-A2C6-4EE2-9A28-7AB59F9EA1D4

Q37999699-A7C82F01-DCF6-4474-BFB1-D1E99B6BA7B1

Q37999699-B4AA62C2-6665-4BFF-9898-A090261A22D2

P304

Q37999699-51801E71-4B32-4B11-B246-5E692FD8CEE8

P31

Q37999699-FA4F7344-910B-4865-A24F-321160DB7423

P356

Q37999699-7F978EE1-E73A-4A1F-A9C6-E6BA13367605

P478

Q37999699-09ACCC68-16EB-4AC4-AF30-9321E01E41F5

P577

Q37999699-1BD0AD9F-DFF4-413D-BB1A-7B319294D70C

P5875

Q37999699-2160952C-AF92-41B8-B785-33C430640B53

P698

Q37999699-7EDC7749-8C69-4495-8047-A0BC3BAFAAEB

P356

P1433

American Journal of Hematology

P1476

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors.

@en

P2093

Alex C Spyropolous

http://www.w3.org/2001/XMLSchema#string

Andra James

http://www.w3.org/2001/XMLSchema#string

Anthony K C Chan

http://www.w3.org/2001/XMLSchema#string

David A Garcia

http://www.w3.org/2001/XMLSchema#string

Elizabeth M Van Cott

http://www.w3.org/2001/XMLSchema#string

Jack Ansell

http://www.w3.org/2001/XMLSchema#string

Jim D Douketis

http://www.w3.org/2001/XMLSchema#string

Mark Crowther

http://www.w3.org/2001/XMLSchema#string

Peter A Kouides

http://www.w3.org/2001/XMLSchema#string

Scott Kaatz

http://www.w3.org/2001/XMLSchema#string

P2860

Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects

Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents.

Apixaban with antiplatelet therapy after acute coronary syndrome.

Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.

Rivaroxaban in patients with a recent acute coronary syndrome.

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

New antithrombotics: the impact on global health care.

Prothrombin complex concentrate for critical bleeding.

P304

S141-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJH.23202

http://www.w3.org/2001/XMLSchema#string

P478

87 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223986122

http://www.w3.org/2001/XMLSchema#string

P698

22473649

http://www.w3.org/2001/XMLSchema#string